Developmental profiles in young children with Prader-Labhart-Willi syndrome: Effects of weight and therapy with growth hormone or coenzyme Q 10

American Journal of Medical Genetics, Part A

Volumn 146, Issue 7, 2008, Pages 873-880

  Eiholzer, Urs ^a   Meinhardt, Udo ^a   Rousson, Valentin ^b   Petrovic, Nelica ^a   Schlumpf, Michael ^a   L'Allemand, Dagmar ^a  

^a Padiatrisch Endokrinologisches Zentrum Zurich   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Body composition; Body weight; Coenzyme Q10 therapy; Fat mass; Growth hormone therapy; Lean mass; Prader Willi syndrome (PWS); Psychomotor development

Indexed keywords

HUMAN GROWTH HORMONE; SANOMIT; UBIDECARENONE; UNCLASSIFIED DRUG;

ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL ARTICLE; DEVELOPMENTAL DISORDER; DISOMY; FAILURE TO THRIVE; HUMAN; INFANT; LEAN BODY WEIGHT; MUSCLE HYPOTONIA; OUTCOME ASSESSMENT; PATIENT CARE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; SCORING SYSTEM; TREATMENT OUTCOME;

DEVELOPMENTAL DISABILITIES; GENOTYPE; GROWTH HORMONE; HUMANS; INFANT; LONGITUDINAL STUDIES; PHENOTYPE; PRADER-WILLI SYNDROME; RETROSPECTIVE STUDIES; SEX FACTORS; UBIQUINONE;

EID: 41849101692     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32137     Document Type: Article

References (51)

1. Bekx MT, Carrel AL, Shriver TC, Li Z, Allen DB. 2003. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi Syndrome. J Pediatr 143:372-376.
2. Brandt I. 1983. Griffiths Entwicklungsskalen zur Beurteilung der Entwicklung in den ersten beiden Lebensjahren. Weinheim & Basel: Beltz Verlag. 121 p.
3. Burd L, Vesely B, Martsolf J, Korbeshian J. 1990. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet 37:97-99.
4. Burman P, Ritzen EM, Lindgren AC. 2001. Endocrine dysfunction in Prader-Willi syndrome: A review with special reference to GH. Endocr Rev 22:787-799.
5. Butler MG, Dasouki M, Bittel D, Hunter S, Naini A, DiMauro S. 2003. Coenzyme Q10 levels in Prader-Willi syndrome: Comparison with obese and non-obese subjects. Am J Med Genet Part A 119A:168-171.
6. Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. 2004. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 113:565-573.
7. Butler MG, Lee P, Whitman BY. 2006. Management of Prader-Willi Syndrome. 3rd edition. New York: Springer. 550 p.
8. Carrel A, Myers S, Whitman B, Allen D. 1999. Growth hormone improves body composition, fat utilization, physical strength and agility in Prader-Willi syndrome: A controlled study. J Pediatr 134:215-221.
9. Carrel AL, Myers SE, Whitman BY, Allen DB. 2002. Benefits of long-term GH therapy in Prader-Willi syndrome: A 4-year study. J Clin Endocrinol Metab 87:1581-1585.
10. Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. 2004. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 145:744-749.
11. Cassidy SB, Forsythe M, Heeger S, Nicholls RD, Schork N, Benn P, Schwartz S. 1997. Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet 68:433-440.
12. Clarke DJ, Boer H, Whittington J, Holland A, Butler J, Webb T. 2002. Prader-Willi syndrome, compulsive and ritualistic behaviours: the first population-based survey. Br J Psychiatry 180:358-362.
13. Eiholzer U. 2001. Prader-Willi syndrome. Effects of human growth hormone treatment. Endocrine Development. Savage, M. O. 1: 1-118. Basel: Karger.
14. Eiholzer U, l'Allemand D. 2000. Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after four years of therapy. Horm Res 53:185-192.
15. Eiholzer U, Whitman BY. 2004. A comprehensive team approach to the management of patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 17:1153-1175.
16. Eiholzer U, Blum WF, Molinari L. 1999. Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. J Pediatr 134:222-225.
17. Eiholzer U, Bachmann S, l'Allemand D. 2000a. Is there a growth hormone deficiency in PWS? Six arguments to support the presence of a hypothalamic GHD in PWS. Horm Res 53:44-52.
18. Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Ellis K. 2000b. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res 53:200-206.
19. Eiholzer U, Malich S, l'Allemand D. 2000c. Does growth hormone therapy improve motor development in infants with Prader-Willi syndrome? Eur J Pediatr 159:299-301.
20. Eiholzer U, Nordmann Y, l'Allemand D, Schlumpf M, Schmid S, Kromeyer-Hauschild K. 2003. Improving body composition and physical activity in Prader-Willi Syndrome. J Pediatr 142:73-78.
21. Eiholzer U, l'Allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C. 2004. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 144:753-758.
22. Eiholzer U, l'Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Grüters A, Simoni M. 2006. Hypothalamic and Gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab 91:892-898.
23. Ekelund U, Ong K, Linne Y, Neovius M, Brage S, Dunger DB, Wareham NJ, Rossner S. 2007. Association of weight gain in infancy and early childhood with metabolic risk in young adults. J Clin Endocrinol Metab 92:98-103.
24. Fusch C, Scharrer B, Hungerland E, Moeller H. 1993. Body water, lean body and fat mass of healthy children as measured by deuterium oxide dilution. Isotopenpraxis Environ Health Stud 29:125-131.
25. Gillessen-Kaesbach G, Gross S, Kaya-Westerloh S, Passarge E, Horsthemke B. 1995. DNA methylation based testing of 450 patients suspected of having Prader-Willi syndrome. J Med Genet 32:88-92.
26. Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB. 2001. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria Pediatrics 108:E92-E97.
27. Holland AJ, Treasure J, Coskeran P, Dallow J. 1995. Characteristics of the eating disorder in Prader-Willi syndrome: Implications for treatment. J Intellect Disabil Res 39:373-381.
28. Latal-Hajnal B, von Siebenthal K, Kovari H, Bucher HU, Largo RH. 2003. Postnatal growth in VLBW infants: Significant association with neurodevelopmental outcome. J Pediatr 143:163-170.
29. Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzen EM. 1998. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 87:28-31.
30. Lindgren AC, Barkeling B, Hagg A, Ritzen EM, Marcus C, Rossner S. 2000. Eating behavior in Prader-Willi syndrome, normal weight, and obese control groups. J Pediatr 137:50-55.
31. Lucas A. 1998. Programming by early nutrition: An experimental approach. J Nutr 128:401S-406S.
32. Malich S, Largo R, Schinzel A, Molinari L, Eiholzer U. 2000. Phenotypic heterogeneity of growth and psychometric intelligence in Prader-Willi syndrome: Variable expression of a contiguous gene syndrome or parent-child resemblance? Am J Med Genet 91:298-304.
33. Miller SP, Riley P, Shevell MI. 1999. The neonatal presentation of Prader-Willi syndrome revisited. J Pediatr 134:226-228.
34. Myers SE, Carrel AL, Whitman BY, Allen DB. 2000. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility and growth in Prader-Willi syndrome. J Pediatr 137:42-49.
35. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. 2007. Two years of growth hormone therapy in young children with Prader-Willi syndrome: Physical and neurodevelopmental benefits. Am \Med Genet Part A 143A-443-448.
36. Ong KK, Loos RJ. 2006. Rapid infancy weight gain and subsequent obesity: Systematic reviews and hopeful suggestions. Acta Paediatr 95:904-908.
37. Prader A, Labhart A, Willi H. 1956. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 86:1260-1261.
38. Prader A, Largo R, Molinari L, Issler C. 1989. Physical growth of Swiss children form birth to 20 years of age. Helv Paediatr Acta 43:1-125.
39. Schlumpf M, Eiholzer U, Gygax M, Schmid S, van dS I, l'Allemand D. 2006. A daily comprehensive muscle training programme increases lean mass and spontaneous activity in children with Prader-Willi syndrome after 6 months. J Pediatr Endocrinol Metab 19:65-74.
40. Schmidt H, Schwarz HP, Enders A. 2001. Dietary intervention in the first four years prevents abnormal weight gain but negatively affects height development in Prader-Willi syndrome. Acta Paediatr 90:468-469.
41. Skuse D, Pickles A, Wolke D, Reilly S. 1994. Postnatal growth and mental development: evidence for a "sensitive period". J Child Psychol Psychiatry 35:521-545.
42. Stadler DD. 1995. Nutritional management. In: Greenswag LR, Alexander R, editors. Management of Prader-Willi syndrome. New York: Springer. p 88-114.
43. Vogels A, Fryns JP. 2004. Age at diagnosis, body mass index and physical morbidity in children and adults with the Prader-Willi syndrome. Genet Couns 15:397-404.
44. Vogels A, Van Den EJ, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP. 2004. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 12:238-240.
45. Whitman BY. 2003. Prader-Willi syndrome: A pervasive neurodevelopmental disorder requiring a multidisciplinary approach. In: Eiholzer U, l'Allemand D, Zipf W, editors. Prader-Willi syndrome as a model for obesity. Basel: Karger. p 200-210.
46. Whitman BY, Accardo P. 1987. Emotional symptoms in Prader Willi syndrome adolescents. Am J Med Genet 28:897-905.
47. Whitman B, Greenswag LR. 1995. Psychological and behavioural management. In: Greenswag LR, Alexander R, editors. Management of Prader Willi Syndrome. New York: Springer. p 125-141.
48. Whitman BY, Myers S, Carrel A, Allen D. 2002. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: A 2-year, controlled study. Pediatrics 109:E35.
49. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. 2001. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 38:792-798.
50. Whittington J, Holland A, Webb T, Butler J, Clarke D, Boer H. 2002. Relationship between clinical and genetic diagnosis of Prader-Willi syndrome. J Med Genet 39:926-932.
51. Wigren M, Hansen S. 2003. Prader-Willi syndrome: Clinical picture, psychosocial support and current management. Child Care Health Dev 29:449-456.